Pfizer Inc. (NYSE: PFE), the world’s largest research-based biopharmaceutical company, is headquartered in New York City and has been a pillar of global healthcare since its founding in 1849. Former Pfizer CEO Ian C. Read led the company from December 2010 through January 2019, steering the pharmaceutical giant through one of the most transformative periods in its history — including the loss of Lipitor exclusivity, major acquisitions such as Hospira and Medivation, and the attempted $160 billion mega-merger with Allergan. A 41-year Pfizer veteran who rose from operational auditor to chairman and CEO, Read is widely regarded as one of the most influential pharmaceutical executives of the 2010s.

(Suggested: Pfizer CEO Email & Net Worth – Albert Bourla Salary)

Ian Read – Quick Facts

Pfizer Competitors

Pfizer Inc. operates in the highly competitive global pharmaceutical and biopharmaceutical industry. During Ian Read’s tenure as CEO and through the present day, Pfizer’s key competitors include:

• Johnson & Johnson – diversified healthcare conglomerate; vaccines and consumer health
• Merck & Co. (MSD) – leader in oncology (Keytruda), vaccines, and infectious diseases
• Roche Holding AG – global leader in oncology and diagnostics
• Novartis AG – Swiss pharma giant with strong biologics and generics (Sandoz) portfolios
• AbbVie Inc. – immunology powerhouse (Humira/Skyrizi); major biosimilar competitor
• AstraZeneca plc – strong oncology and respiratory pipeline; COVID-19 vaccine rival
• Sanofi S.A. – French pharma leader in vaccines, rare diseases, and immunology
• GlaxoSmithKline plc (GSK) – vaccines and respiratory medicines

Ian Read Net Worth 2026 – Pfizer CEO Salary

As of 2026, Ian Read’s net worth is estimated at approximately $147 million USD, based on his accumulated Pfizer stock holdings, prior compensation, and investment activities. Read holds approximately 1.12 million shares of Pfizer stock worth roughly $30.6 million at current prices (PFE ~$27.37 as of February 2026). His wealth also reflects decades of executive compensation totaling well over $150 million during his career at Pfizer.

During his final years as CEO, Pfizer’s board substantially increased Read’s pay to retain his leadership. His peak compensation year was 2017, when he earned $27.9 million — a 61% increase over his 2016 pay — driven largely by a special $8 million retention equity award. In his final year as CEO (2018), his total compensation was $19.5 million, reflecting his transition to the executive chairman role.

Ian Read Compensation History (FY2016–FY2018)

Pfizer Net Worth 2026 – Company Financials

Pfizer Inc. remains one of the world’s most valuable pharmaceutical companies. Under current CEO Albert Bourla, Pfizer delivered strong full-year 2024 results with revenues of $63.6 billion. The company’s market capitalization stands at approximately $155.7 billion as of February 2026 (PFE trading at ~$27.37).

Pfizer Financial Summary (FY2024)

(Recommended: Steven Collis, AmerisourceBergen CEO)

Contact Ian Read – Email Address | LinkedIn

Ian Read is no longer an active executive at Pfizer. Below are his known contact details and corporate affiliations:

Career & Education – Company, University, & College

Ian Read is the quintessential company lifer, having spent his entire 41-year career at Pfizer Inc. before retiring. He joined the company in 1978 as an operational auditor, fresh from qualifying as a Chartered Accountant. Over four decades, he held senior positions spanning international operations, finance, and executive leadership across Latin America, Europe, the Middle East, Africa, and Canada.

Read’s early career took him through Pfizer’s fastest-growing emerging markets. He served as Chief Financial Officer of Pfizer Mexico and Country Manager of Pfizer Brazil, gaining deep operational experience in Latin American markets. In 1996, he was appointed President of the International Pharmaceuticals Group overseeing Latin America and Canada.

His rise to the top accelerated in the 2000s: he became Executive Vice President for Europe in 2000, was named Corporate Vice President in 2001, and took on responsibility for Canada in addition to Europe in 2002. From 2006 to 2010, he served as Senior Vice President and Group President of Worldwide Biopharmaceutical Businesses, Pfizer’s largest division.

In December 2010, Read replaced Jeffrey Kindler as CEO at a critical juncture — Pfizer was facing the patent expiration of Lipitor, the best-selling drug in pharmaceutical history. He also became Chairman of the Board in 2011. Under his leadership, Pfizer pursued aggressive M&A including the $17 billion acquisition of Hospira and the $14 billion acquisition of Medivation, while also attempting the historic (but ultimately blocked) $160 billion merger with Allergan.

(Related: Pradeep Dadha, Netmeds CEO)

Ian Read Career Timeline

Education

Ian Read Wiki – Age, Family, & More

Ian C. Read (age ~72–73 as of 2026) was born in Forfar, Scotland in 1953. His mother was Scottish, and his parents returned to Rhodesia (now Zimbabwe) when he was six weeks old, where he grew up. He later moved to England for his university education at Imperial College London, graduating with a B.Sc. in Chemical Engineering in 1974 before qualifying as a Chartered Accountant in 1978.

Read is a dual British-American citizen and has been an American citizen for many years. He keeps his personal and family life private — details about his spouse and children are not publicly disclosed. He is known to enjoy golf and owns a vacation home near Bonita Springs, Florida, where several Pfizer directors have also resided, including former CEO William Steere.

Notable Achievements & Board Positions

• 41-Year Pfizer Veteran – One of the longest-serving executives in Pfizer’s 175-year history
• Post-Lipitor Transformation – Led Pfizer through the loss of Lipitor exclusivity, the best-selling drug ever ($125B+ cumulative revenue)
• Major M&A Architect – Oversaw acquisitions of Hospira ($17B), Medivation ($14B), and the attempted Allergan merger ($160B)
• DXC Technology Chairman – Named Board Chairman of DXC Technology in February 2020
• The Carlyle Group – Serves as Operating Executive at the global investment firm since 2020
• Kimberly-Clark Board – Served on the board of directors of the consumer products giant
• AIChE Supporter – Active supporter of the American Institute of Chemical Engineers

(Suggested: Larry Merlo, CVS CEO)

About Pfizer Inc.

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at 66 Hudson Boulevard East, New York City. Founded in 1849 by Charles Pfizer and Charles F. Erhart in Brooklyn, New York, Pfizer has grown into one of the world’s largest and most influential pharmaceutical companies. The company trades on the New York Stock Exchange under the ticker symbol PFE.

Pfizer discovers, develops, manufactures, and sells medicines, vaccines, and consumer healthcare products worldwide. Key product areas include:

With approximately 118,000 employees worldwide and operations in more than 125 countries, Pfizer generated $63.6 billion in revenue in FY2024. The company achieved historic prominence during the COVID-19 pandemic through its partnership with BioNTech to develop the Comirnaty vaccine and the Paxlovid antiviral treatment.

Frequently Asked Questions (FAQ)

Who is Ian Read and what is his role at Pfizer?

Ian C. Read is a Scottish-born British-American business executive who served as Chairman and CEO of Pfizer Inc. from December 2010 to January 2019. He joined Pfizer in 1978 and spent 41 years at the company, rising from operational auditor to the top leadership position. After stepping down as CEO, he served as Executive Chairman until December 2019 before fully retiring from Pfizer. He was succeeded as CEO by Dr. Albert Bourla.

What is Ian Read’s net worth in 2026?

As of 2026, Ian Read’s net worth is estimated at approximately $147 million USD. This includes approximately 1.12 million shares of Pfizer stock worth roughly $30.6 million, accumulated compensation from his decades-long Pfizer career, and earnings from his current roles at The Carlyle Group and DXC Technology.

What was Ian Read’s salary as Pfizer CEO?

Ian Read’s peak total compensation as Pfizer CEO was $27.9 million in 2017, which included a $1.96 million base salary, $2.6 million bonus, $13.1 million in stock awards, and a special $8 million retention equity award. In his final year as CEO (2018), his total compensation was $19.5 million. Over his tenure as CEO (2010–2018), his annual compensation typically ranged from $17–28 million.

Who replaced Ian Read as Pfizer CEO?

Dr. Albert Bourla, a Greek-American veterinarian and business executive, replaced Ian Read as Pfizer CEO on January 1, 2019. Bourla had previously served as Pfizer’s Chief Operating Officer. Under Bourla’s leadership, Pfizer developed the groundbreaking COVID-19 vaccine (Comirnaty) in partnership with BioNTech, making Pfizer a household name worldwide during the pandemic.

Where did Ian Read go to university?

Ian Read earned a Bachelor of Science in Chemical Engineering from Imperial College London in 1974. He subsequently qualified as a Chartered Accountant through the Institute of Chartered Accountants of England and Wales (ICAEW) in 1978, the same year he joined Pfizer as an operational auditor.

What is Ian Read doing after retiring from Pfizer?

Since retiring from Pfizer in December 2019, Ian Read has taken on several prominent board and advisory roles. He was named Board Chairman of DXC Technology in February 2020 and serves as an Operating Executive at The Carlyle Group, a global investment firm. He has also served on the board of directors of Kimberly-Clark Corporation. In October 2024, Read publicly commented on Starboard Value’s activist campaign at Pfizer alongside former CFO Frank D’Amelio.

Article last updated:February 2026March 2, 2026